Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00350701 · ClinicalTrials.gov registry record · Phase 4

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

A Phase 4 study, sponsored by University at Buffalo.

Completed
Registry status
Phase 4
Development phase
49
Enrollment target

NCT00350701 is a Phase 4 study that has completed, run by University at Buffalo. The registered enrollment target is 49 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00350701, a Phase 4 study, has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
Phase 4
Development phase
49 participants
Enrollment target

Study Summary

This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.

Interventions

  • DRUG placebo
  • DRUG androgel
  • DRUG androgel 10g

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2006-07
Est. Completion 2013-07
Phase Phase 4

Sponsor

University at Buffalo

67 total trials

What the Registry Record Tells You About NCT00350701

The ClinicalTrials.gov registry entry for NCT00350701 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00350701 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00350701 about?

NCT00350701 is a clinical study titled "Effect of Androgel on Type 2 Diabetic Males With Hypogonadism". This is to study the effect of replacing testosterone on different inflammatory cells in type 2 diabetics with low testosterone levels.

What is the current status of trial NCT00350701?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2006-07. Estimated completion is 2013-07.

What interventions are being tested in trial NCT00350701?

The interventions under investigation include: placebo (DRUG), androgel (DRUG), androgel 10g (DRUG).

Who is sponsoring clinical trial NCT00350701?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.